Breakthrough Healthcare

The Fund’s investment objective is to achieve medium to long-term capital appreciation through the active management of a diversified portfolio of equity and fixed income funds. The portfolio presents a high exposure to equity securities issued by companies operating in the medical and biotech sectors, with a focus on new medical frontiers, such as genome sequencing and editing. The secular trend of digital health will also be significantly influenced in the future by the demographic curve and the population aging. The portfolio average equity exposure is around 30% for the Conservative risk class, 60% for the Balanced and 90% for the Aggressive.

To find out more about the fund profiles, take a look at the FAQ.